Lupin inks licensing pact with US firm for biosimilar

Drug maker Lupin on Thursday said it has inked a licensing pact with US-based Valorum Biologics to commercialise Armlupeg, a biosimilar indicated for the treatment of neutropenia in cancer patients.

Under the terms of the agreement, Valorum will advance the commercialisation and distribution of Armlupeg (pegfilgrastim-unne) in the US, while Lupin will be responsible for manufacturing and supply of the product and will receive an upfront license fee and a royalty payment on net sales.

''This partnership reflects our unwavering commitment to improving patient outcomes and aligns with our mission to make high-quality biosimilars more accessible. We look forward to strengthening our presence in the US biosimilars market and building on our momentum as a global leader in developing and commercializing important biosimilar medicines,'' said Spiro Gavaris, President – US Generics, Lupin.

Armlupeg is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.

''Our team has a proven track record in specialty markets, and we expect to capture significant market share through our commercial expertise,'' Valorum CEO Par S Hyare stated.

Lupin shares ended 0.55 per cent up at Rs 2,091.95 apiece on BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)